Vaderis Therapeutics Raises $152M for Rare Disease Drug

Vaderis Therapeutics has successfully closed an oversubscribed $152 million Series B financing round, a significant capital infusion aimed at advancing its lead candidate, engasertib, through pivotal clinical development for hereditary hemorrhagic telangiectasia (HHT). The funding, which is expected to carry the company through potential U.S. regulatory approval, underscores robust investor confidence in the targeted therapy's potential to address a critical unmet need in the rare vascular disorder space.

The substantial financing was co-led by prominent life sciences investors Goldman Sachs Alternatives and TCGX. The round saw strong participation from a distinguished syndicate including Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, alongside existing backers Medicxi and Droia. This broad support from both new and returning investors highlights a collective belief in Vaderis' scientific approach and the therapeutic promise of engasertib.

Concurrent with the financing, Vaderis has initiated the global Phase 3 HEROIC study for engasertib. This pivotal trial will evaluate the efficacy and safety of the once-daily oral AKT inhibitor in patients suffering from moderate-to-severe HHT. The initiation of this large-scale study marks a crucial transition for Vaderis, moving from earlier-stage validation to definitive clinical assessment, a critical step in bringing a novel treatment to market for a condition with no current approved therapies.

Engasertib's development is built upon compelling proof-of-concept and long-term extension data, previously published in The New England Journal of Medicine. These findings demonstrated clinically meaningful and sustained improvements across various disease measures in HHT patients, providing a strong scientific rationale for its advancement. The drug targets the AKT pathway, a novel approach for HHT, a genetic disorder characterized by abnormal blood vessel formation, leading to significant bleeding complications.

The rare disease therapeutics market continues to attract significant investment, driven by the potential for high unmet need and specialized patient populations. Companies like Vaderis, focusing on genetically defined conditions with clear therapeutic targets, are well-positioned to capture investor interest. The $152 million raised by Vaderis places it among well-capitalized biotechs aiming to navigate the complex path to regulatory approval and commercialization in this specialized sector.

Azmi Nabulsi, President and Chief Executive Officer of Vaderis Therapeutics, expressed optimism about the milestone, stating, "Today represents a defining moment for HHT patients. Closing this financing and initiating HEROIC as the first Phase 3 study utilizing a molecule specifically developed for HHT marks an exciting new chapter." He further acknowledged the contributions of patients, investigators, and advocacy groups, alongside the crucial support from their investor base.

The strategic composition of Vaderis' Board of Directors, featuring representatives from key investors such as Giovanni Mariggi (Medicxi), Colin Walsh (Goldman Sachs Alternatives), and Giuliano Marostica (TCGX), alongside independent directors, signals a strong governance structure prepared to guide the company through its next phase of growth and clinical execution.